JP2006525995A5 - - Google Patents

Download PDF

Info

Publication number
JP2006525995A5
JP2006525995A5 JP2006507483A JP2006507483A JP2006525995A5 JP 2006525995 A5 JP2006525995 A5 JP 2006525995A5 JP 2006507483 A JP2006507483 A JP 2006507483A JP 2006507483 A JP2006507483 A JP 2006507483A JP 2006525995 A5 JP2006525995 A5 JP 2006525995A5
Authority
JP
Japan
Prior art keywords
use according
cells
therapeutic agent
antibody
allogeneic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006507483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525995A (ja
Filing date
Publication date
Priority claimed from US10/404,662 external-priority patent/US20040197312A1/en
Application filed filed Critical
Publication of JP2006525995A publication Critical patent/JP2006525995A/ja
Publication of JP2006525995A5 publication Critical patent/JP2006525995A5/ja
Withdrawn legal-status Critical Current

Links

JP2006507483A 2003-04-02 2004-03-24 サイトカイン発現細胞ワクチンの組み合わせ Withdrawn JP2006525995A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/404,662 US20040197312A1 (en) 2003-04-02 2003-04-02 Cytokine-expressing cellular vaccine combinations
PCT/US2004/008846 WO2004093831A2 (en) 2003-04-02 2004-03-24 Cytokine-expressing cellular vaccine combinations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011175553A Division JP5607000B2 (ja) 2003-04-02 2011-08-11 サイトカイン発現細胞ワクチンの組み合わせ

Publications (2)

Publication Number Publication Date
JP2006525995A JP2006525995A (ja) 2006-11-16
JP2006525995A5 true JP2006525995A5 (enExample) 2007-05-24

Family

ID=33096962

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006507483A Withdrawn JP2006525995A (ja) 2003-04-02 2004-03-24 サイトカイン発現細胞ワクチンの組み合わせ
JP2011175553A Expired - Fee Related JP5607000B2 (ja) 2003-04-02 2011-08-11 サイトカイン発現細胞ワクチンの組み合わせ
JP2014084319A Pending JP2014169299A (ja) 2003-04-02 2014-04-16 サイトカイン発現細胞ワクチンの組み合わせ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011175553A Expired - Fee Related JP5607000B2 (ja) 2003-04-02 2011-08-11 サイトカイン発現細胞ワクチンの組み合わせ
JP2014084319A Pending JP2014169299A (ja) 2003-04-02 2014-04-16 サイトカイン発現細胞ワクチンの組み合わせ

Country Status (5)

Country Link
US (3) US20040197312A1 (enExample)
EP (3) EP1608321A4 (enExample)
JP (3) JP2006525995A (enExample)
CA (1) CA2519563A1 (enExample)
WO (1) WO2004093831A2 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7297204B2 (en) 2004-02-18 2007-11-20 Meadwestvaco Corporation Water-in-oil bituminous dispersions and methods for producing paving compositions from the same
JP2006265155A (ja) * 2005-03-23 2006-10-05 Link Genomics Kk 癌の免疫療法
CN101355928B (zh) * 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
EP2010207A4 (en) * 2006-03-22 2009-12-02 Imp Innovations Ltd COMPOSITIONS AND METHODS RELATING TO THE MODULATION OF COMPONENTS OF THE IMMUNE SYSTEM
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
CA2652599C (en) * 2006-05-03 2019-09-24 Ross Kedl Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
EP2073837B1 (en) * 2006-10-06 2014-06-25 Bavarian Nordic Inc. Recombinant modified vaccinia ankara virus encoding a her-2 antigen in combination with a taxane for use in treating cancer
US20080181874A1 (en) * 2007-01-29 2008-07-31 Alexander Kharazi Cell composition and method for treating cancer
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2009032256A2 (en) * 2007-08-30 2009-03-12 Cell Genesys, Inc. Apc activators in combination with a cytokine-secreting cell and methods of use thereof
ES2336873B1 (es) * 2007-11-07 2011-01-24 Proyecto De Biomedicina Cima, S.L. Composicion farmaceutica para el tratamiento de cancer.
US8475785B2 (en) 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
EP2987856B1 (en) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
WO2011136828A1 (en) * 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
WO2012054425A2 (en) * 2010-10-18 2012-04-26 University Of Iowa Research Foundation Biodegradable particulate formulations
CN103611163A (zh) 2011-09-05 2014-03-05 韩美科学株式会社 一种包含干扰素α-缀合物的抗癌用药物组合物
JP2014527983A (ja) * 2011-09-19 2014-10-23 ザ ジョンズ ホプキンス ユニバーシティー 癌免疫療法
AU2013271375B2 (en) * 2012-06-08 2018-03-22 Aduro Biotech, Inc. Compositions and methods for cancer immunotherapy
EP2879498A4 (en) * 2012-07-30 2016-03-30 Alex Wah Hin Yeung BY TREATMENT OF AT LEAST TWO OR ALL THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE TEST MODULE DEVELOPED TUMOR SPECIFIC LIVING AND IN VIVO CANCER VACCINE SYSTEM
MD4655C1 (ro) 2013-03-14 2020-06-30 Icahn School Of Medicine At Mount Sinai Virusurile bolii de Newcastle şi utilizarea acestora
WO2014157692A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
US20170000832A1 (en) 2014-02-27 2017-01-05 Viralytics Limited Combination method for treatment of cancer
WO2015131176A1 (en) * 2014-02-28 2015-09-03 Podack Eckhard R Compositions, methods, and kits for treatment of cancer
AU2015315324A1 (en) * 2014-09-08 2017-03-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer comprising administering a PPAR-gamma agonist
EP3208872B1 (en) * 2014-10-15 2020-04-22 Sumitomo Chemical Company, Ltd. Positive electrode active material for lithium secondary battery, positive electrode for lithium secondary battery, and lithium secondary battery
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
SG11201705844SA (en) 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
CN107708725A (zh) * 2015-04-02 2018-02-16 坎库雷有限公司 用于引发免疫应答的剂和组合物
TWI716405B (zh) 2015-05-07 2021-01-21 美商艾吉納斯公司 抗ox40抗體及其使用方法
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
EP3299028B1 (en) * 2015-05-20 2024-10-30 Sumitomo Pharma Co., Ltd. Combination of wt1 antigen peptide, immunomodulator and wt1 helper peptide
LT3303396T (lt) 2015-05-29 2023-01-10 Bristol-Myers Squibb Company Antikūnai prieš ox40 ir jų panaudojimo būdai
ES2987376T3 (es) * 2015-06-29 2024-11-14 Verastem Inc Composiciones terapéuticas, combinaciones y métodos de uso
CN109516981B (zh) 2015-07-13 2019-10-22 大连万春布林医药有限公司 普那布林组合物
EP3383430A4 (en) 2015-12-02 2019-12-18 Agenus Inc. ANTIBODIES AND METHOD FOR USE THEREOF
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
KR20240091084A (ko) 2016-06-06 2024-06-21 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
WO2017223090A1 (en) * 2016-06-21 2017-12-28 The Trustees Of Columbia University In The City Of New York Whole-cell based vaccine against zika virus
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
EP3549957A4 (en) 2016-11-30 2020-08-05 Sumitomo Dainippon Pharma Co., Ltd. AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
IL268305B2 (en) 2017-02-01 2024-08-01 Beyondspring Pharmaceuticals Inc Plinabulin in combination with one or more g-csf drug for use in the therapeutic treatment of docetaxel-induced
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
EP4599893A3 (en) 2017-04-14 2025-11-05 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
US11786523B2 (en) 2018-01-24 2023-10-17 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia
WO2019222423A1 (en) * 2018-05-15 2019-11-21 The Brigham And Women's Hospital, Inc. Compositions and methods related to tumor cell killers and vaccines
US20210177952A1 (en) * 2018-08-16 2021-06-17 Beyondspring Pharmaceuticals, Inc. Method and composition for stimulating immune response
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease
WO2021076811A1 (en) * 2019-10-15 2021-04-22 Moderna TX, Inc. Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
TWI776276B (zh) * 2019-11-13 2022-09-01 中國醫藥大學 異種組織細胞組合物治療癌症之用途
JP2023504659A (ja) 2019-12-03 2023-02-06 ニューボーゲン，インコーポレイティド 腫瘍細胞ワクチン
JP2024513505A (ja) 2021-04-09 2024-03-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 腫瘍を治療するための組成物及び方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5098702A (en) * 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
EP0432216A1 (en) * 1988-09-01 1991-06-19 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US6303121B1 (en) * 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5266491A (en) * 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
JP3051411B2 (ja) * 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
US5436146A (en) * 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
DK0551401T3 (da) 1990-09-14 1996-01-22 Univ Texas Fremgangsmåde og præparater til genterapi og potensering af antitumor-immunitet
US5674486A (en) * 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US7211259B1 (en) * 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US5674704A (en) * 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
US6506604B2 (en) * 1993-06-11 2003-01-14 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
JP2911056B2 (ja) * 1995-04-08 1999-06-23 株式会社エルジ化学 ヒト４−１ｂｂに特異的なモノクローナル抗体およびこれを産生する細胞株
US6093570A (en) * 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6040183A (en) * 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6033674A (en) * 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US6805869B2 (en) * 1996-06-12 2004-10-19 Shanghai Cp Guojian Pharmaceutical Co., Ltd. Cellular vaccines and immunotherapeutics and methods for their preparation
CA2268340A1 (en) * 1996-10-11 1998-04-23 Bristol-Myers Squibb Company Methods and compositions for immunomodulation
DE69824859T2 (de) 1997-04-14 2005-08-04 Cell Genesys, Inc., Foster City Methoden zur erhöhung der effizienz rekombinanter aav produkte
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US6037177A (en) * 1997-08-08 2000-03-14 Cell Genesys, Inc. Method for increasing the efficiency of recombinant AAV production
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
AU741602B2 (en) * 1998-02-02 2001-12-06 Johns Hopkins University School Of Medicine, The A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
WO2000026676A1 (en) * 1998-11-03 2000-05-11 Cell Genesys, Inc. Cancer-associated antigens and methods of their identification
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
AU774962B2 (en) * 1998-12-03 2004-07-15 Regents Of The University Of California, The Stimulation of T cells against self antigens using CTLA-4 blocking agents
US20030035790A1 (en) * 1999-01-15 2003-02-20 Shu-Hsia Chen Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
AU5458500A (en) 1999-06-02 2000-12-18 Cell Genesys, Inc. Regulation of systemic immune responses utilizing cytokines and antigens
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
CN1168740C (zh) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
US20050053579A1 (en) * 2001-10-23 2005-03-10 Jacques Galipeau Novel synthetic chimeric fusion transgene with immuno-therapeutic uses
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US7176022B2 (en) * 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products

Similar Documents

Publication Publication Date Title
JP2006525995A5 (enExample)
Tai et al. Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells
JP2018502120A5 (enExample)
AU2015219495B2 (en) Disease therapy by inducing immune response to Trop-2 expressing cells
NZ704295A (en) Compositions and methods for the treatment of infections and tumors
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2007092939A8 (en) Antigenic gm-csf peptides and antibodies to gm-csf
RU2019114963A (ru) Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo
Watkins-Yoon et al. CTX-8573, an innate-cell engager targeting BCMA, is a highly potent multispecific antibody for the treatment of multiple myeloma
JP2019532047A5 (enExample)
ATE412425T1 (de) Neue krebsbehandlung
Pai et al. Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels
JP2014523398A5 (enExample)
EP4371610A3 (en) Topical treatment of inflammatory bowel disease using antibodies and fragments thereof
Jain et al. Radiation therapy as a bridging strategy for refractory diffuse large B cell lymphoma patients awaiting CAR T manufacturing of axicabtagene ciloleucel
WO2011056566A3 (en) Compounds and methods for treatment of cancer
Bell et al. Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy
Wang et al. Cord blood-derived cytokine-induced killer cellular therapy plus radiation therapy for esophageal cancer: a case report
Leung Immunotherapy in acute leukemia
Fischer et al. RIG-I-induced type I IFNs promote regeneration of the intestinal stem cell compartment during acute tissue damage
Arai et al. Enhanced expression of CXCR4 facilitates the trafficking of anti-C-kit chimeric antigen receptor (CAR) T cells to bone marrow and achieves effective donor stem cell engraftment
Das et al. Blockade of IL-23 Signaling Results in Targeted Protection of the Colon and Allows for Separation of Graft Versus Host and Graft Versus Leukemia Effects.
Halimi et al. Manifestations vasculaires et rénales des anti-angiogéniques; classification et prise en charge
Kata et al. Occurrence and Treatment of Isolated Extramedullary Relapses after Allogeneic Hematopoietic Stem Cell Transplantation for Leukaemias: A Single Institute Experience with 442 Patients.
Nekhlyudov Cancer Treatment